Brief: HBM Holdings Says Jury Returns Verdict In Favor Of Harbour Antibodies Against Amgen IN U.S. Patent Case
15/06/2026 02:56
BRIEF-HBM Holdings Says Jury Returns Verdict In Favor Of Harbour Antibodies Against Amgen IN U.S. Patent Case June 15 (Reuters) - Hbm Holdings Ltd 2142.HK:
JURY VERDICT IN U.S. PATENT INFRINGEMENT LITIGATION
JURY RETURNS VERDICT IN FAVOR OF HARBOUR ANTIBODIES AGAINST AMGEN IN U.S. PATENT CASE
HARBOUR ANTIBODIES IS ENTITLED TO DAMAGES OF US$20.2 MILLION BEING FULL AMOUNT REQUESTED AT TRIAL
IF SUCH ENHANCED DAMAGES ARE GRANTED IN FULL, AWARD COULD INCREASE TO UP TO APPROXIMATELY US$60.6 MILLION
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study